DiaMedica Therapeutics Announces Regulatory Approval to Begin Phase 2 Trial of DM199 in the Treatment of Preeclampsia
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) has received regulatory approval to initiate a Phase 2 clinical trial for DM199, its proprietary recombinant serine protease, in the treatment of preeclampsia. The South African Health Products Regulatory Authority (SAHPRA) has approved the planned two-part study, which will be conducted at Tygerberg Hospital in Cape Town, South Africa. Prof. Catherine Cluver, MD, PhD will lead the investigator-sponsored trial as principal investigator.
The company expects to begin dosing in the fourth quarter of 2024, with top-line results for Part 1a anticipated in the first half of 2025. DiaMedica believes DM199 has the potential to be a disease-modifying therapy for preeclampsia, targeting placental perfusion, fetal growth, maternal blood pressure, and endothelial health.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) ha ricevuto l'approvazione regolatoria per avviare un trial clinico di Fase 2 per DM199, il suo proteasi serina ricombinante proprietario, nel trattamento della preeclampsia. L'Autorità Regolatoria dei Prodotti Sanitari del Sud Africa (SAHPRA) ha approvato lo studio pianificato in due parti, che sarà condotto presso l'Ospedale di Tygerberg a Città del Capo, Sud Africa. La Prof.ssa Catherine Cluver, MD, PhD sarà la responsabile dello studio sponsorizzato dagli investigatori.
L'azienda prevede di iniziare la somministrazione nel quarto trimestre del 2024, con i risultati preliminari per la Parte 1a attesi nel primo semestre del 2025. DiaMedica crede che DM199 abbia il potenziale per essere una terapia modificante la malattia per la preeclampsia, mirando alla perfusione placentare, alla crescita fetale, alla pressione sanguigna materna e alla salute endoteliale.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) ha recibido la aprobación regulatoria para iniciar un ensayo clínico de Fase 2 para DM199, su proteasa de serina recombinante de propiedad, en el tratamiento de la preeclampsia. La Autoridad Reguladora de Productos de Salud de Sudáfrica (SAHPRA) ha aprobado el estudio planificado en dos partes, que se llevará a cabo en el Hospital de Tygerberg en Ciudad del Cabo, Sudáfrica. La Prof. Catherine Cluver, MD, PhD será la investigadora principal en el ensayo patrocinado por investigadores.
La empresa espera comenzar la dosificación en el cuarto trimestre de 2024, con los resultados principales de la Parte 1a anticipados para la primera mitad de 2025. DiaMedica cree que DM199 tiene el potencial de ser una terapia modificadora de la enfermedad para la preeclampsia, enfocándose en la perfusión placentaria, el crecimiento fetal, la presión arterial materna y la salud endotelial.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC)는 2상 임상 시험을 시작하기 위한 규제 승인을 받았습니다. 이 시험은 자사의 독점 재조합 세린 프로테아제 DM199를 자간증 치료에 사용할 예정입니다. 남아프리카 보건 제품 규제 당국(SAHPRA)은 케이프타운의 타이거버그 병원에서 실시될 예정인 두 부분으로 나누어진 연구를 승인했습니다. 캐서린 클루버 박사(MD, PhD)가 주 연구 책임자로 이 시험을 이끌 것입니다.
회사는 2024년 4분기에 투여를 시작할 것으로 예상하며, 1a 부분의 주요 결과는 2025년 상반기에 나올 것으로 보입니다. DiaMedica는 DM199가 자간증에 대해 질병 수정 치료제가 될 가능성이 있다고 믿고 있으며, 유도태반관류, 태아 성장, 모체혈압 및 내피 건강에 목표를 두고 있습니다.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) a reçu l'approbation réglementaire pour initier un essai clinique de phase 2 pour DM199, sa protéase sérique recombinante de propriété, dans le traitement de la prééclampsie. L'Autorité réglementaire sud-africaine des produits de santé (SAHPRA) a approuvé l'étude en deux parties prévue, qui sera réalisée à l'hôpital de Tygerberg à Cape Town, Afrique du Sud. Le Professeur Catherine Cluver, MD, PhD, dirigera l'essai sponsorisé par les enquêteurs en tant qu'investigateur principal.
L'entreprise s'attend à commencer à doser au quatrième trimestre 2024, avec des résultats préliminaires pour la partie 1a prévus dans la première moitié de 2025. DiaMedica croit que DM199 a le potentiel d'être une thérapie modifiant la maladie pour la prééclampsie, ciblant la perfusion placentaire, la croissance fœtale, la pression artérielle maternelle et la santé endothéliale.
DiaMedica Therapeutics Inc. (Nasdaq: DMAC) hat die regulatorische Genehmigung erhalten, um eine Phase-2-Studie für DM199, sein proprietäres rekombinantes Serinprotease, zur Behandlung von Preeclampsie zu beginnen. Die südafrikanische Arzneimittelbehörde (SAHPRA) hat die geplante zweigeteilte Studie genehmigt, die im Tygerberg-Krankenhaus in Kapstadt, Südafrika, durchgeführt wird. Prof. Catherine Cluver, MD, PhD wird die als Prüfer geförderte Studie als Hauptprüfer leiten.
Das Unternehmen erwartet, die Dosen im vierten Quartal 2024 zu beginnen, wobei die Ergebnisse für Teil 1a im ersten Halbjahr 2025 erwartet werden. DiaMedica ist der Ansicht, dass DM199 das Potenzial hat, eine krankheitsmodifizierende Therapie für Preeclampsie zu sein, die auf die Plazentaperfusion, das fetale Wachstum, den Blutdruck der Mutter und die endotheliale Gesundheit zielt.
- Regulatory approval received for Phase 2 clinical trial of DM199 in preeclampsia
- Dosing expected to commence in Q4 2024
- Top-line results for Part 1a anticipated in H1 2025
- Potential to be the first therapeutic option for preeclampsia
- None.
Insights
This regulatory approval for DiaMedica Therapeutics to begin a Phase 2 trial of DM199 for preeclampsia treatment is a significant milestone. Preeclampsia is a serious pregnancy complication with treatment options, so a potential new therapy could be groundbreaking. Key points to consider:
- The trial will be conducted in South Africa, potentially accelerating recruitment in a high-risk population
- Preliminary results are expected in H1 2025, providing a near-term catalyst
- DM199's mechanism targets multiple aspects of preeclampsia pathophysiology, including placental perfusion, fetal growth and maternal blood pressure
- If successful, this could be the first disease-modifying therapy for preeclampsia
While promising, investors should note that Phase 2 trials still carry significant risk. The
This news represents a positive development for DiaMedica Therapeutics, potentially expanding their pipeline and addressable market. Key financial implications include:
- No immediate revenue impact, but positive data could drive valuation
- Increased R&D expenses expected as the trial progresses
- Potential for partnerships or increased investor interest if preliminary data is promising
- The global preeclampsia therapeutics market is projected to reach
$1.8 billion by 2027, offering significant revenue potential
With a market cap of
- Dosing first participant expected in the fourth quarter of 2024 with preliminary proof-of-concept results targeted for the first half of 2025
“We are excited to receive regulatory approval and are eager to advance our Phase 2 clinical trial of DM199 for preeclampsia.” said Rick Pauls, President and Chief Executive Officer of DiaMedica. “This trial marks a significant milestone in our efforts to develop the first therapeutic option for this serious unmet medical need.”
Dr. Lorianne Masuoka, Chief Medical Officer of DiaMedica, added, “We believe that DM199 has the potential to be a disease-modifying therapy for preeclampsia, based on its mechanism of action. Specifically, we believe that DM199 targets and has the potential to improve placental perfusion and enhance fetal growth, while also lowering maternal blood pressure and improving endothelial health. The data anticipated from Part 1a of the study should provide strong proof of concept for DM199's potential as a disease-modifying therapy, thereby increasing the likelihood of prolongation of gestational days and a healthier baby and mother.”
About Preeclampsia
Preeclampsia is a serious pregnancy disorder that typically develops after the 20th week of gestation, characterized by high blood pressure and damage to organ systems, often the kidneys and liver. Affecting up to
About the Preeclampsia Phase 2 Trial
This Phase 2 open-label, single center, single-arm, safety and pharmacodynamic, proof-of-concept, investigator-sponsored study of DM199 in treating preeclampsia will be conducted at the Tygerberg Hospital,
About DM199
DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1 (rhKLK1) in clinical development for acute ischemic stroke and preeclampsia. KLK1 is a serine protease enzyme that plays an important role in the regulation of diverse physiological processes via a molecular mechanism that increases production of nitric oxide, prostacyclin and endothelium-derived hyperpolarizing factor. In preeclampsia, DM199 is intended to lower maternal blood pressure, enhance endothelial health and improve perfusion to maternal organs and the placenta. In the case of acute ischemic stroke, in which DiaMedica is also studying the use of DM199, DM199 is intended to enhance blood flow and boost neuronal survival in the ischemic penumbra by dilating arterioles surrounding the site of the vascular occlusion and inhibition of apoptosis (neuronal cell death) while also facilitating neuronal remodeling through the promotion of angiogenesis.
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious ischemic diseases with a focus on acute ischemic stroke and preeclampsia. DiaMedica’s lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality in
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the
View source version on businesswire.com: https://www.businesswire.com/news/home/20241009958356/en/
Scott Kellen
Chief Financial Officer
Phone: (763) 496-5118
skellen@diamedica.com
For Investor Inquiries:
Mike Moyer
Managing Director, LifeSci Advisors, LLC
mmoyer@lifesciadvisors.com
Source: DiaMedica Therapeutics Inc.
FAQ
What is the purpose of DiaMedica's Phase 2 trial for DM199 (DMAC)?
When is DiaMedica (DMAC) expected to begin dosing in the Phase 2 trial for DM199?
Where will DiaMedica's Phase 2 trial for DM199 (DMAC) be conducted?